Product image of Lacosamide Mylan (Lacosamide) supplied by GNH India

Lacosamide Mylan

Active Ingredient:
Lacosamide
Origin:
EU

Lacosamide Mylan (Lacosamide)

Lacosamide, the active ingredient in Lacosamide Mylan, is an anticonvulsant presented as a tablet for oral use. It treats partial‑onset seizures and epilepsy in patients who require seizure control.

GNH India supplies Lacosamide Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Mylan S.P.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lacosamide is an anticonvulsant used in the management of seizure disorders.
  • Partial‑onset seizures: reduces the frequency and severity of focal seizures.
  • Epilepsy: provides adjunctive therapy for patients with refractory epilepsy.

How It Works

  • Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes, stabilising hyper‑excitable neuronal membranes and decreasing repetitive neuronal firing that underlies seizure activity.

Side Effects

Lacosamide may cause a range of adverse reactions, from mild to serious.

Common Side Effects

  • Dizziness: transient sensation of light‑headedness.
  • Nausea: mild gastrointestinal upset.
  • Fatigue: feeling unusually tired.
  • Headache: mild to moderate pain.
  • Tremor: involuntary shaking of limbs.
  • Diplopia: temporary double vision.

Serious or Rare Side Effects

  • Cardiac arrhythmia: abnormal heart rhythm, especially PR‑interval prolongation.
  • Severe skin reactions: such as Stevens‑Johnson syndrome.
  • Suicidal thoughts: emergence of depressive symptoms.
  • Hepatic dysfunction: elevated liver enzymes.
  • Allergic reaction: rash, swelling, or anaphylaxis.

Precautions & Warnings

  • Before prescribing Lacosamide, clinicians should consider several safety factors.
  • Cardiac monitoring: assess baseline ECG and monitor PR interval.
  • Renal impairment: adjust use in patients with severe kidney dysfunction.
  • Hepatic disease: evaluate liver function prior to initiation.
  • Pregnancy and lactation: weigh potential risks as safety data are limited.
  • Drug‑specific warnings: avoid abrupt discontinuation to reduce seizure recurrence.
  • Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Lacosamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers: may reduce lacosamide plasma levels.
  • Concomitant class III anti‑arrhythmics: increase risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely)

  • Other antiepileptics (e.g., carbamazepine, phenytoin): may alter seizure control.
  • CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation.
  • Alcohol: can increase dizziness and coordination problems.

Frequently Asked Questions

Lacosamide Mylan is an oral anticonvulsant indicated for the treatment of partial‑onset (focal) seizures and as adjunctive therapy in patients with epilepsy who need additional seizure control.

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilising neuronal membranes and reducing the repetitive firing of neurons that contributes to seizure generation.

The dosage of Lacosamide Mylan is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Specific dosing regimens are not provided here.

Safety data for Lacosamide in pregnancy and lactation are limited. Clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing individuals.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can offer an alternative for patients who have inadequate response or intolerable side effects with other agents.

Store Lacosamide Mylan at ambient temperature, below 25 °C, in the original packaging. Protect it from moisture, excessive heat and direct sunlight to maintain product stability.

Lacosamide Mylan is taken orally, usually as a tablet, and should be swallowed whole with water. The exact administration schedule is determined by the prescribing healthcare professional.

Serious risks include cardiac arrhythmias such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and rare psychiatric effects including suicidal thoughts. Patients should be monitored for these events.

Patients with known hypersensitivity to lacosamide or any component of the formulation should avoid it. Caution is also advised for individuals with significant cardiac conduction disorders or uncontrolled hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lacosamide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT